Sjögren's syndrome and Neuromyelitis Optica spectrum disorders (NMOSD) - a case report and review of literature

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Jayarangaiah, Apoorva ^a   Sehgal, Rahul ^a   Epperla, Narendranath ^a  

^a MARSHFIELD CLINIC   (United States)

Author keywords

Aquaporin 4 antibody; Neuromyelitis optica; Neuromyelitis optica spectrum disorders; Sjogren's syndrome

Indexed keywords

ACICLOVIR; AQUAPORIN 4 ANTIBODY; CYCLOPHOSPHAMIDE; GADOLINIUM; IMMUNOGLOBULIN G ANTIBODY; MEPREDNISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLIGOCLONAL BAND; PREDNISONE; IMMUNOSUPPRESSIVE AGENT;

ADD ON THERAPY; ADULT; ARM WEAKNESS; ARTICLE; BURNING SENSATION; CASE REPORT; CEREBROSPINAL FLUID; CERVICAL SPINAL CORD; CLONUS; CONTRAST ENHANCEMENT; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; HEMIPARESIS; HERPES ZOSTER; HUMAN; HYPERESTHESIA; HYPERREFLEXIA; LIMB DYSESTHESIA; LIMB WEAKNESS; MAINTENANCE THERAPY; MIDDLE AGED; MOBILIZATION; MUSCLE HYPERTONIA; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEOCYTOSIS; RELAPSE; REPEAT PROCEDURE; SJOEGREN SYNDROME; STEROID THERAPY; THORACIC SPINE; TREATMENT DURATION; URINE INCONTINENCE; COMORBIDITY; IMMUNOLOGY; NEUROMYELITIS OPTICA; SJOGREN'S SYNDROME;

COMORBIDITY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; NEUROMYELITIS OPTICA; SJOGREN'S SYNDROME;

EID: 84907958849     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-014-0200-5     Document Type: Article

References (31)

1. Ramos-Casala M, Anaya JM, Garcia-Carrasco M, Rosas J, Bové A, Claver G, Diaz LA, Herrero C, Font J. Cutaneous vasculitis in primary Sjogren's syndrome: classification and clinical significance of 52 patients. Medicine 2004, 83:96-100. 10.1097/01.md.0000119465.24818.98.
2. Theodoridou A, Settas L. Demyelination in rheumatic diseases. Postgrad Med J 2008, 84:127-132. 10.1136/jnnp.2005.075861, 18372483.
3. Sa MJ. Acute transverse myelitis: a practical reappraisal. Autoimmun Rev 2009, 9:128-131. 10.1016/j.autrev.2009.04.005, 19389491.
4. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for Neuromyelitis Optica. Neurology 2006, 66:1485-1489. 10.1212/01.wnl.0000216139.44259.74, 16717206.
5. Jacob J, McKeon A, Nakashima I, Sato DK, Elsone L, Fujihara K, de Seze J. Current concept of neuromyelitis optica and neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 2013, 84:922-930. 10.1136/jnnp-2012-302310, 23142960.
6. Pierot L, Sauve C, Leger JM, Martin N, Koeger AC, Wechsler B, Chiras J. Asymptomatic cerebral involvement in Sjögren's syndrome: MRI findings of 15 cases. Neuroradiology 1993, 35:378-380. 10.1007/BF00588375, 8327117.
7. Nitescu D, Nicolau A, Caraiola S, Predeteanu D, Ionescu R, Tanasescu C. Neuromyelitis optica- complication or comorbidity of primary Sjögren's syndrome. Rom J Intern Med 2011, 49:295-300. 22568275.
8. Sofat N, Venables PJ. Is Sjogren's myelopathy Devic Disease?. Ann Rheum Dis 2008, 67:730-731. 10.1136/ard.2007.077883, 18408117.
9. Spezialetti R, Bluestein HG, Peter JB, Alexander EL. Neuropsychiatric disease in Sjogren's syndrome: anti-ribosomal P and anti-neuronal antibodies. Am J Med 1993, 95:153-160. 10.1016/0002-9343(93)90255-N, 8356981.
10. Alexander EL, Malinow K, Lejewski JE, Jerdan MS, Provost TT, Alexander GE: Primary Sjogren's syndrome with central nervous system disease mimicking multiple sclerosis.Ann Intern Med 1986, 104:323..
11. Olsen ML, O'Connor S, Arnett FC, Rosenbaum D, Grotta JC, Warner NB: Autoantibodies and rheumatic disorders in a neurology inpatient population: a prospective study.Am J Med 1991, 90:479..
12. Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, Lennon VA. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006, 59:566-569. 10.1002/ana.20770, 16453327.
13. Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C, Agre P, Ottersen OP. Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci 1997, 17:171-180. 8987746.
14. Kira J. Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: astrocytopathy as a common denominator in demyelinating disorders. J Neurol Sci 2011, 311:69-77. 10.1016/j.jns.2011.08.043, 21962794.
15. Wandinger KP, Stangel M, Witte T, Venables P, Charles P, Jarius S, Wildemann B, Probst C, Iking-Konert C, Schneider M. Autoantibodies against aquaporin-4 in patients with neuro-psychiatric systemic lupus erythematous and primary Sjogren's syndrome. Arthritis Rheum 2010, 62:1198-1200. 10.1002/art.27337, 20131265.
16. Weinshenker B, Wingerchuk D, Pittock S. NMO-IgG a specific biomarker for neuromyelitis optica. Dis Markers 2006, 22:197-206. 10.1155/2006/586306, 17124341.
17. Jarius S, Paul F, Franciotta D. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 2008, 4:202-214. 18334978.
18. Uzawa A, Mori M, Masuda S, Kuwabara S. Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica. Arch Neurol 2011, 68:913-917. 10.1001/archneurol.2011.148, 21747031.
19. Kinoshita M, Nakatsuji Y, Moriya M, Okuno T, Kumanogoh A, Nakano M, Takahashi T, Fujihara K, Tanaka K, Sakoda S. Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport 2009, 20:508-512. 10.1097/WNR.0b013e32832776f4, 19297740.
20. Icoz S, Tuzun E, Kurtuncu M, Durmus H, Mutlu M, Eraksoy M, Akman-Demir G. Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci 2010, 120:71-75. 10.3109/00207450903428970, 20128675.
21. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 2006, 441:235-238. 10.1038/nature04753, 16648838.
22. Marignier R, Nicolle A, Watrin C, Touret M, Cavagna S, Varrin-Doyer M, Cavillon G, Rogemond V, Confavreux C, Honnorat J, Giraudon P. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain 2010, 133:2578-2591. 10.1093/brain/awq177, 20688809.
23. Luchinetti F. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125:1450-1461. 10.1093/brain/awf151.
24. Sato D, Callegaro D, Lana-Peixoto MA, Fujihara K. Brazilian Committee for treatment and research in multiple sclerosis. Treatment of neuromyelitis optica; evidence based review. Arq Neuropsiquiatr 2012, 70:59-66. 10.1590/S0004-282X2012000100012, 22218475.
25. Sellner J, Hemmer B, Mühlau M. The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes. J Autoimmun 2010, 34:371-379. 10.1016/j.jaut.2009.09.013, 19853412.
26. Heerlein K, Jarius S, Jacobi C. Aquaporin-4 antibody positive longitudinally extensive transverse myelitis following varicella zoster infection. J Neurol Sci 2009, 276:184-186. 10.1016/j.jns.2008.08.015, 18805556.
27. Wingerchuck DM, Hogancamp WF, O'Brien PC. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999, 53:1107-1114. 10.1212/WNL.53.5.1107.
28. Jacob A, Matiello M, Weinshenker BG, Lucchinetti C, Shuster E, Carter J, Keegan BM, Kantarci OH, Pittock SJ. Treatment of neuromyelitis optica with Mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009, 66:1128-1133. 10.1001/archneurol.2009.175, 19752302.
29. Falcini F, Trapani S, Ricci L, Resti M, Simonini G, de Martino M. Sustained improvement of a girl affected with Devic's disease over 2 years of Mycophenolate mofetil treatment. Rheumatology (Oxford) 2006, 45:913-915. 10.1093/rheumatology/kei263.
30. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011, 68:1412-1420. 10.1001/archneurol.2011.154, 21747007.
31. Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, DeAngelis T, Matiello M, Cree BA. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008, 65:1443-1448. 10.1001/archneur.65.11.noc80069, 18779415.